Literature DB >> 12695164

Primary Sjögren's syndrome associated agranulocytosis: a benign disorder?

P Coppo1, J Sibilia, F Maloisel, M-H Schlageter, A-L Voyer, V Gouilleux-Gruart, J Goetz, B Desablens, B Tribout, K Lassoued.   

Abstract

OBJECTIVE: To report on an uncommon association of agranulocytosis in primary Sjögren's syndrome (SS).
METHODS: The clinical, haematological, and immunological features of seven patients with primary SS associated with a chronic (>6 months) agranulocytosis, and the outcome of the patients, were analysed.
RESULTS: Patients were white women with an unexplained agranulocytosis. They all had non-erosive arthritis and three had a thrombocytopenia or Evan's syndrome. In three patients, transient or durable expansion of T lymphocytes was present in the peripheral blood or in the bone marrow, but evolved independently from neutrophil counts. There was no paroxysmal nocturnal haemoglobinuria clone or antibodies to neutrophil surface antigens. In vitro bone marrow culture was normal (four patients) or showed a decrease in colony forming unit-granulocyte monocyte (CFU-GM) and colony forming unit-erythroblast (CFU-E) (one patient). Serum levels of soluble Fas ligand (sFasL) were normal, and granulocyte-colony stimulating factor (G-CSF) concentrations were either normal or raised. One patient was treated with steroids associated with intravenous immunoglobulins and achieved a lasting response. Two other patients were treated with steroids and methotrexate, with poor efficacy. Short courses of subcutaneous G-CSF produced a transient and mild response in all three patients. Complete recovery of the neutrophils occurred temporarily during pregnancy in two patients. After a mean follow up of 34.8 months (range 6-139) all patients were alive and none developed serious infections.
CONCLUSION: A subset of patients with primary SS and non-destructive arthritis may develop a chronic but well tolerated agranulocytosis that is usually poorly responsive to steroids and oral methotrexate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695164      PMCID: PMC1754540          DOI: 10.1136/ard.62.5.476

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  Clinical analysis of primary Sjögren's syndrome complicating anemia.

Authors:  Jing-Guo Zhou; Yu-Feng Qing; Li Jiang; Qi-Bin Yang; Wen-Feng Luo
Journal:  Clin Rheumatol       Date:  2010-02-20       Impact factor: 2.980

Review 2.  [Rheumatic and hemato-/oncological disorders].

Authors:  M A Reuss-Borst
Journal:  Z Rheumatol       Date:  2005-02       Impact factor: 1.372

Review 3.  Primary Sjögren's syndrome: new clinical and therapeutic concepts.

Authors:  M Ramos-Casals; A G Tzioufas; J Font
Journal:  Ann Rheum Dis       Date:  2004-10-21       Impact factor: 19.103

4.  Clinical Phenotype and Mechanisms of Leukopenia/Neutropenia in Patients with Primary Sjögren's Syndrome.

Authors:  Ioanna E Stergiou; Efstathia E Kapsogeorgou; Athanasios G Tzioufas; Michalis Voulgarelis; Andreas V Goules
Journal:  Mediterr J Rheumatol       Date:  2022-03-31

5.  The spectrum of chronic CD8+ T-cell expansions: clinical features in 14 patients.

Authors:  Etienne Ghrenassia; Louise Roulin; Aude Aline-Fardin; Christophe Marzac; Frédéric Féger; Julie Gay; Jérome Pacanowski; Alexandre Hertig; Paul Coppo
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

Review 6.  Ocular manifestations of idiopathic aplastic anemia: retrospective study and literature review.

Authors:  Ahmad M Mansour; Jong Wook Lee; Seung Ah Yahng; Kyu Seop Kim; Maha Shahin; Nelson Hamerschlak; Rubens N Belfort; Shree K Kurup
Journal:  Clin Ophthalmol       Date:  2014-04-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.